The angiotensin II type 1 receptor antagonist (angio-tensin receptor blocker [ARB]) losartan has been shown in the LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) study to ...

Several clinical trials have demonstrated the relative tolerability of losartan. [8,14,18,19,20] The most frequent adverse reaction, as observed in a clinical trial of 2900 patients assessing the ...